Modification by ubiquitin-like proteins: Significance in apoptosis and autophagy pathways

International Journal of Molecular Sciences

Volumn 13, Issue 9, 2012, Pages 11804-11831

  Cajee, Umar Faruq ^a   Hull, Rodney ^a   Ntwasa, Monde ^a  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

Apoptosis; Autophagy; Cancer; DWNN; Immune response; P53; SNAMA; Ubiquitin like; Ubiquitin proteasome; Ubls

Indexed keywords

ANTINEOPLASTIC AGENT; ARSENIC TRIOXIDE; AUTOPHAGY RELATED PROTEIN 12; AUTOPHAGY RELATED PROTEIN 8; BORTEZOMIB; HBX 41108; HERPUD 1; HLA F ADJACENT TRANSCRIPT 10; INTERFERON STIMULATED GENE FACTOR 15; NEDD8 PROTEIN; NUTLIN; PARKIN; PEPTIDES AND PROTEINS; PROTEIN DERIVATIVE; PROTEIN DOMAIN WITH NO NAME; RETINOBLASTOMA BINDING PROTEIN; RETINOBLASTOMA BINDING PROTEIN 6; SUMO 1 PROTEIN; SUMO 2 PROTEIN; SUMO 3 PROTEIN; SUMO 4 PROTEIN; SUMO PROTEIN; TRANSCRIPTION FACTOR; UBIQUILIN; UBIQUITIN; UBIQUITIN FOLD MODIFIER 1; UBIQUITIN LIKE PROTEIN; UBIQUITIN RELATED MODIFIER 1; UNCLASSIFIED DRUG; UNINDEXED DRUG; [4 [4 [(2,3 DIHYDRO 1H INDEN 1 YL)AMINO] 7H PYRROLO[2,3 D]PYRIMIDIN 7 YL] 2 HYDROXYCYCLOPENTYLMETHYL] SULFAMATE;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; AUTOPHAGY; AUTOPHAGY RELATED GENE 12; AUTOPHAGY RELATED GENE 8; CANCER CHEMOTHERAPY; CELL PROTECTION; DISEASE ASSOCIATION; DRUG MECHANISM; DRUG POTENTIATION; FATYLATION; GENE; GENETIC IDENTIFICATION; HODGKIN DISEASE; HUMAN; IMMUNE RESPONSE; INNATE IMMUNITY; ISGYLATION; MULTIPLE MYELOMA; NEDDYLATION; NEOPLASM; NONHUMAN; NUCLEOTIDE SEQUENCE; PARKIN GENE; PHYLOGENY; PROMYELOCYTIC LEUKEMIA; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN MODIFICATION; PROTEIN STRUCTURE; REVIEW; SEQUENCE ALIGNMENT; SUMO 2 GENE; SUMO 4 GENE; SUMOYLATION; UBIQUITIN LIKE DOMAIN;

EID: 84866913822     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms130911804     Document Type: Review

References (149)

1. Kerscher, O.; Felberbaum, R.; Hochstrasser, M. Modification of proteins by ubiquitin and ubiquitin-like proteins. Annu. Rev. Cell Dev. Biol. 2006, 22, 159-180.
2. Hershko, A. The ubiquitin system for protein degradation and some of its roles in the control of the cell division cycle. Cell Death Differ. 2005, 12, 1191-1197.
3. Sadeh, R.; Breitschopf, K.; Bercovich, B.; Zoabi, M.; Kravtsova-Ivantsiv, Y.; Kornitzer, D.; Schwartz, A.; Ciechanover, A. The N-terminal domain of MyoD is necessary and sufficient for its nuclear localization-dependent degradation by the ubiquitin system. Proc. Natl. Acad. Sci. USA 2008, 105, 15690-15695.
4. Ciechanover, A.; Ben-Saadon, R. N-terminal ubiquitination: More protein substrates join in. Trends Cell Biol. 2004, 14, 103-106.
5. Fajerman, I.; Schwartz, A.L.; Ciechanover, A. Degradation of the Id2 developmental regulator: Targeting via N-terminal ubiquitination. Biochem. Biophys. Res.Commun. 2004, 314, 505-512.
6. Hershko, A.; Ciechanover, A. The ubiquitin system. Annu. Rev. Biochem. 1998, 67, 425-479.
7. Jentsch, S.; Pyrowolakis, G. Ubiquitin and its kin: How close are the family ties? Trends Cell Biol. 2000, 10, 335-341.
8. Herrmann, J.; Lerman, L.O.; Lerman, A. Ubiquitin and ubiquitin-like proteins in protein regulation. Circ. Res. 2007, 100, 1276-1291.
9. Bohren, K.M.; Nadkarni, V.; Song, J.H.; Gabbay, K.H.; Owerbach, D. A M55V polymorphism in a novel SUMO gene (SUMO-4) differentially activates heat shock transcription factors and is associated with susceptibility to type I diabetes mellitus. J. Biol. Chem. 2004, 279, 27233-27238.
10. Odagiri, S.; Tanji, K.; Mori, F.; Kakita, A.; Takahashi, H.; Kamitani, T.; Wakabayashi, K. Immunohistochemical analysis of Marinesco bodies, using antibodies against proteins implicated in the ubiquitin-proteasome system, autophagy and aggresome formation. Neuropathology 2012, 261-266.
11. Zhao, C.; Denison, C.; Huibregtse, J.M.; Gygi, S.; Krug, R.M. Human ISG15 conjugation targets both IFN-induced and constitutively expressed proteins functioning in diverse cellular pathways. Proc. Natl. Acad. Sci. USA 2005, 102, 10200-10205.
12. French, S.W.; Bardag-Gorce, F.; French, B.A.; Li, J.; Oliva, J. The role of innate immunity in the pathogenesis of preneoplasia in drug-induced chronic hepatitis based on a mouse model. Exp Mol Pathol 2011, 91, 653-659.
13. McNally, T.; Huang, Q.; Janis, R.S.; Lui, Z.; Olejniczak, E.T.; Reilly, R.M. Structural analysis of UBL5, a novel ubiquitin-like modifier. Protein Sci. 2003, 12, 1562-1566.
14. Allende-Vega, N.; Dayal, S.; Agarwala, U.; Sparks, A.; Bourdon, J.C.; Saville, M.K. p53 is activated in response to disruption of the pre-mRNA splicing machinery. Oncogene 2012, doi:10.1038/onc.2012.38.
15. Kas, K.; Michiels, L.; Merregaert., J. Genomic structure and expression of the human fau gene: Encoding the ribosomal protein S30 fused to a ubiquitin-like protein. Biochem. Biophys. Res. Commun. 1992, 187, 927-933.
16. Geng, J.; Klionsky, D.J. The Atg8 and Atg12 ubiquitin-like conjugation systems in macroautophagy. EMBO Rep. 2008, 9, 859-864.
17. Sasakawa, H.; Sakata, E.; Yamaguchi, Y.; Komatsu, M.; Tatsumi, K.; Kominami, E.; Tanaka, K.; Kato, K. Solution structure and dynamics of Ufm1, a ubiquitin-fold modifier 1. Biochem. Biophys. Res. Commun. 2006, 343, 21-26.
18. Mather, A.; Rakghotho, M.; Ntwasa, M. SNAMA, a novel protein with a DWNN domain and a RING finger-like motif: A possible role in apoptosis. Biochim. Biophys. Acta 2005, 1727, 169-176.
19. Schlieker, C.D.; van der Veen, A.G.; Damon, J.R.; Spooner, E.; Ploegh, H.L. A functional proteomics approach links the ubiquitin-related modifier Urm1 to a tRNA modification pathway. Proc. Natl. Acad. Sci. USA 2008, 105, 18255-18260.
20. Matunis, M.J.; Coutavas, E.; Blobel, G. A novel ubiquitin-like modification modulates the partitioning of the Ran-GTPase-activating protein ranGAP1 between the cytosol and the nuclear pore complex. J. Cell Biol. 1996, 135, 1457-1470.
21. Jurgen Dohmen, R. SUMO protein modification. Biochim. Biophys. Acta (BBA)-Mol. Cell Res. 1695, 113-131.
22. Bayer, P.; Arndt, A.; Metzger, S.; Mahajan, R.; Melchior, F.; Jaenicke, R.; Becker, J. Structure determination of the small ubiquitin-related modifier SUMO-1. J. Mol. Biol. 1998, 280, 275-286.
23. Meulmeester, E.; Melchior, F. Cell biology: SUMO. Nature 2008, 452, 709-711.
24. Johnson, E.S. Protein modification by SUMO. Annu. Rev. Biochem. 2004, 73, 355-382.
25. Su, H.-L.; Li, S.S.L. Molecular features of human ubiquitin-like SUMO genes and their encoded proteins. Gene 2002, 296, 65-73.
26. Hay, R.T. SUMO-specific proteases: A twist in the tail. Trends Cell Biol. 2007, 17, 370-376.
27. Tatham, M.H.; Jaffray, E.; Vaughan, O.A.; Desterro, J.M.P.; Botting, C.H.; Naismith, J.H.; Hay, R.T. Polymeric chains of SUMO-2 and SUMO-3 are conjugated to protein substrates by SAE1/SAE2 and ubc9. J. Biol. Chem. 2001, 276, 35368-35374.
28. Rodriguez, M.S.; Dargemont, C.; Hay, R.T. SUMO-1 conjugation in vivo requires both a consensus modification motif and nuclear targeting. J. Biol. Chem. 2001, 276, 12654-12659.
29. Castillo-Lluva, S.; Tatham, M.H.; Jones, R.C.; Jaffray, E.G.; Edmondson, R.D.; Hay, R.T.; Malliri, A. SUMOylation of the GTPase Rac1 is required for optimal cell migration. Nat. Cell Biol. 2010, 12, 1078-1085.
30. Marx, J. SUMO wrestles its way to prominence in the cell. Science 2005, 307, 836-839.
31. Hay, R.T.; Vuillard, L.; Desterro, J.M.P.; Rodriguez, M.S. Control of NF-kB transcriptional activation by signal induced proteolysis of IKBa. Phil. Trans. R. Soc. Lond. B 1999, 354, 1601-1609.
32. Mabb, A.; Miyamoto, S. SUMO and NF-kB ties. Cell Mol. Life Sci. 2007, 64, 1979-1996.
33. Kirsh, O.; Seeler, J.-S.; Pichler, A.; Gast, A.; Muller, S.; Miska, E.; Mathieu, M.; Harel-Bellan, A.; Kouzarides, T.; Melchior, F.; et al. The SUMO E3 ligase RanBP2 promotes modification of the HDAC4 deacetylase. EMBO J. 2002, 21, 2682-2691.
34. Yamamoto, H.; Ihara, M.; Matsuura, Y.; Kikuchi, A. Sumoylation is involved in [beta]-catenin-dependent activation of Tcf-4. EMBO J. 2003, 22, 2047-2059.
35. Ihara, M.; Yamamoto, H.; Kikuchi, A. SUMO-1 modification of PIASy, an E3 ligase, is necessary for PIASy-dependent activation of Tcf-4. Mol. Cell Biol. 2005, 25, 3506-3518.
36. Goodson, M.L.; Hong, Y.; Rogers, R.; Matunis, M.J.; Park-Sarge, O.-K.; Sarge, K.D. SUMO-1 modification regulates the DNA binding activity of heat shock transcription factor 2, a promyelocytic leukemia nuclear body associated transcription factor. J. Biol. Chem. 2001, 276, 18513-18518.
37. Stehmeier, P.; Muller, S. Regulation of p53 family members by the ubiquitin-like SUMO system. DNA Repair. 2009, 8, 491-498.
38. Rodriguez, M.S.; Desterro, J.M.P.; Lain, S.; Midgley, C.A.; Lane, D.P.; Hay, R.T. SUMO-1 modification activates the transcriptional response of p53. EMBO J. 1999, 18, 6455-6461.
39. Hoege, C.; Pfander, B.; Moldovan, G.-L.; Pyrowolakis, G.; Jentsch, S. RAD6-dependent DNA repair is linked to modification of PCNA by ubiquitin and SUMO. Nature 2002, 419, 135-141.
40. Bergink, S.; Jentsch, S. Principles of ubiquitin and SUMO modifications in DNA repair. Nature 458, 461-467.
41. Owerbach, D.; McKay, E.M.; Yeh, E.T.H.; Gabbay, K.H.; Bohren, K.M. A proline-90 residue unique to SUMO-4 prevents maturation and sumoylation. Biochem. Biophys. Res. Commun. 337, 517-520.
42. Kumar, S.; Yoshida, Y.; Noda, M. Cloning of a cDNA which encodes a novel ubiquitin-like protein. Biochem. Biophys. Res. Commun. 1993, 195, 393-399.
43. Ohki, Y.; Funatsu, N.; Konishi, N.; Chiba, T. The mechanism of poly-NEDD8 chain formation in vitro. Biochem. Biophys. Res. Commun. 2009, 381, 443-447.
44. Liakopoulos, D.; Doenges, G.; Matuschewski, K.; Jentsch, S. A novel protein modification pathway related to the ubiquitin system. EMBO J. 1998, 17, 2208-2214.
45. Hori, T.; Osaka, F.; Chiba, T.; Miyamoto, C.; Okabayashi, K.; Shimbara, N.; Kato, S.; Tanaka, K. Covalent modification of all members of human cullin family proteins by NEDD8. Oncogene 1999, 18, 6829-6834.
46. Kawakami, T.; Chiba, T.; Suzuki, T.; Iwai, K.; Yamanaka, K.; Minato, N.; Suzuki, H.; Shimbara, N.; Hidaka, Y.; Osaka, F.; et al. NEDD8 recruits E2-ubiquitin to SCF E3 ligase. EMBO J. 2001, 20, 4003-4012.
47. Watson, I.R.; Irwin, M.S.; Ohh, M. NEDD8 pathways in cancer, sine quibus non. Cancer Cell 2011, 19, 168-176.
48. Deshaies, R.J.; Emberley, E.D.; Saha, A. Control of cullin-ring ubiquitin ligase activity by Nedd8. Subcell. Biochem. 2010, 54, 41-56.
49. Sarikas, A.; Hartmann, T.; Pan, Z.-Q. The cullin protein family. Genome Biol. 2011, 12, 220.
50. Liu, L.; Lee, S.; Zhang, J.; Peters, S.B.; Hannah, J.; Zhang, Y.; Yin, Y.; Koff, A.; Ma, L.; Zhou, P. CUL4A abrogation augments DNA damage response and protection against skin carcinogenesis. Mol. Cell 2009, 34, 451-460.
51. Du, J.; Zhang, J.; Su, Y.; Liu, M.; Ospina, J.K.; Yang, S.; Zhu, A. J. In vivo RNAi screen reveals Neddylation genes as novel regulators of Hedgehog signaling. PLoS One 2011, 6, e24168.
52. Gao, F.; Cheng, J.; Shi, T.; Yeh, E.T.H. Neddylation of a breast cancer-associated protein recruits a class III histone deacetylase that represses NFKB-dependent transcription. Nat. Cell Biol. 2006, 8, 1171-1177.
53. Stickle, N.H.; Chung, J.; Klco, J.M.; Hill, R.P.; Kaelin, W.G., Jr.; Ohh, M. pVHL modification by NEDD8 is required for fibronectin matrix assembly and suppression of tumor development. Mol. Cell Biol. 2004, 24, 3251-3261.
54. Xirodimas, D.P.; Sundqvist, A.; Nakamura, A.; Shen, L.; Botting, C.; Hay, R.T. Ribosomal proteins are targets for the NEDD8 pathway. EMBO Rep. 2008, 9, 280-286.
55. Shamay, M.; Greenway, M.; Liao, G.; Ambinder, R.F.; Hayward, D. De novo DNA methyltransferase DNMT3b interacts with NEDD8-modified proteins. J. Biol. Chem. 2010, 285, 36377-36386.
56. Broemer, M.; Tenev, T.; Rigbolt, K.T.G.; Hempel, S.; Blagoev, B.; Silke, J.; Ditzel, M.; Meier, P. Systematic in vivo RNAi analysis identifies IAPs as NEDD8-E3 ligases. Mol. Cell 40, 810-822.
57. Fan, W.; Cai, W.; Parimoo, S.; Lennon, G.G.; Weissman, S.M. Identification of seven new human MHC class I region genes around the HLA-F locus. Immunogenetics 1996, 44, 97-103.
58. Liu, Y.-C.; Pan, J.; Zhang, C.; Fan, W.; Collinge, M.; Bender, J.R.; Weissman, S.M. A MHC-encoded ubiquitin-like protein (FAT10) binds noncovalently to the spindle assembly checkpoint protein MAD2. Proc. Natl. Acad. Sci. USA 1999, 96, 4313-4318.
59. Lee, C.G.; Ren, J.; Cheong, I.S.; Ban, K.H.; Ooi, L.L.; Tan, S.Y.; Kan, A.; Nuchprayoon, I.; Jin, R.; Lee, K.-H.; et al. Expression of the FAT10 gene is highly upregulated in hepatocellular carcinoma and other gastrointestinal and gynecological cancers Oncogene 2003, 22, 2592-2603.
60. Aichem, A.; Pelzer, C.; Lukasiak, S.; Kalveram, B.; Sheppard, P.W.; Rani, N.; Schmidtke, G.; Groettrup, M. USE1 is a bispecific conjugating enzyme for ubiquitin and FAT10, which FAT10ylates itself in cis. Nat. Commun. 2010, 1, doi:10.1038/ncomms1012.
61. Chiu, Y.H.; Sun, Q.; Chen, Z.J. E1-L2 activates both ubiquitin and FAT10. Mol. Cell Biol. 2007, 1014-1023.
62. Lukasiak, S.; Schiller, C.; Oehlschlaeger, P.; Schmidtke, G.; Krause, P.; Legler, D.F.; Autschbach, F.; Schirmacher, P.; Breuhahn, K.; Groettrup, M. Proinflammatory cytokines cause FAT10 upregulation in cancers of liver and colon. Oncogene 2008, 27, 6068-6074.
63. Canaan, A.; Yu, X.; Booth, C.J.; Lian, J.; Lazar, I.; Gamfi, S.L.; Castille, K.; Kohya, N.; Nakayama, Y.; Liu, Y.-C. et al. FAT10/Diubiquitin-like protein-deficient mice exhibit minimal phenotypic differences. Mol. Cell Biol. 2006, 26, 5180-5189.
64. Gong, P.; Canaan, A.; Wang, B.; Leventhal, J.; Snyder, A.; Nair, V.; Cohen, C.D.; Kretzler, M.; D'Agati, V.; Weissman, S. et al. The ubiquitin-like protein FAT10 mediates NF-kB activation. J. Am. Soc. Nephrol. 2010, 21, 316-326.
65. Li, T.; Santockyte, R.; Yu, S.; Shen, R.-F.; Tekle, E.; Lee, C.G.L.; Yang, D.C.H.; Chock, P.B. FAT10 modifies p53 and upregulates its transcriptional activity. Arch. Biochem. Biophys. 2011, 509, 164-169.
66. Ren, J.; Wang, Y.; Gao, Y.; Mehta, S.B.K.; Lee, C.G.L. FAT10 mediates the effect of TNF-a in inducing chromosomal instability. J. Cell Sci. 2011, 124, 3665-3675.
67. Raasi, S.; Schmidtke, G.; Groettrup, M. The ubiquitin-like protein FAT10 forms covalent conjugates and induces apoptosis. J. Biol. Chem. 2001, 276, 35334-35343.
68. Buchsbaum, S.; Bercovich, B.; Ciechanover, A. FAT10 is a proteasomal degradation signal that is itself regulated by ubiquitination. Mol. Biol. Cell 2012, 23, 225-232.
69. Zhang, D.W.; Jeang, K.T.; Lee, C.G.L. p53 negatively regulates the expression of FAT10, a gene upregulated in various cancers. Oncogene 2006, 25, 2318-2327.
70. Doyle, S.E.; Vaidya, S.A.; O'Connell, R.; Dadgostar, H.; Dempsey, P.W.; Wu, T.-T.; Rao, G.; Sun, R.; Haberland, M.E.; Modlin, R.L. et al. IRF3 mediates a TLR3/TLR4-specific antiviral gene program. Immunity 2002, 17, 251-263.
71. Martensen, P.M. Small ISGs coming forward. J. Interferon Cytokine Res. 2004, 24, 1-19.
72. Reich, N.; Evans, B.; Levy, D.; Fahey, D.; Knight, E., Jr.; Darnell, J.E., Jr. Interferon-induced transcription of a gene encoding a 15-kDa protein depends on an upstream enhancer element (promoter/transcription regulation). Proc. Natl. Acad. Sci. USA 1987, 84, 6394-6398.
73. Hummer, B.T.; Li, X.L.; Hassel, B.A. Role for p53 in gene induction by double-stranded RNA. J. Virol. 2001, 75, 7774-7777.
74. Jeon, Y.J.; Yoo, H.M.; Chung, C.H. ISG15 and immune diseases. Biochim. Biophys. Acta Mol. Basis Dis. 2010, 1802, 485-496.
75. Zou, W.; Zhang, D.-E. The interferon-inducible ubiquitin-protein isopeptide ligase (E3) EFP also functions as an ISG15 E3 ligase. J. Biol. Chem. 2006, 281, 3989-3994.
76. Wong, J.J.Y.; Pung, Y.F.; Sze, N.S.-K.; Chin, K.-C. HERC5 is an IFN-induced HECT-type E3 protein ligase that mediates type I IFN-induced ISGylation of protein targets. Proc. Natl. Acad. Sci. USA 2006, 103, 10735-10740.
77. Van der Veen, A.G.; Ploegh, H.L. Ubiquitin-like proteins. Annu. Rev. Biochem. 2012, 81, 323-357.
78. Skaug, B.; Chen, Z.J. Emerging role of ISG15 in antiviral immunity. Cell 2010, 143, 187-190.
79. Durfee, L.A.; Lyon, N.; Seo, K.; Huibregtse, J.M. The ISG15 conjugation system broadly targets newly synthesized proteins: Implications for the antiviral function of ISG15. Mol. Cell 2010, 38, 722-732.
80. Nisole, S.; Stoye, J.P.; Saib, A. Trim family proteins: Retroviral restriction and antiviral defense. Nat. Rev. Microbiol. 2005, 3, 799-808.
81. Nakasato, N.; Ikeda, K.; Urano, T.; Horie-Inoue, K.; Takeda, S.; Inoue, S. A ubiquitin E3 ligase Efp is up-regulated by interferons and conjugated with ISG15. Biochem. Biophys. Res. Commun.351, 540-546.
82. Lenschow, D.J.; Giannakopoulos, N.V.; Gunn, L.J.; Johnston, C.; O'Guin, A.K.; Schmidt, R.E.; Levine, B.; Virgin, H.W., IV. Identification of interferon-stimulated gene 15 as an antiviral molecule during sindbis virus infection in vivo. J. Virol. 2005, 79, 13974-13983.
83. Lenschow, D.J.; Lai, C.; Frias-Staheli, N.; Giannakopoulos, N.V.; Lutz, A.; Wolff, T.; Osiak, A.; Levine, B.; Schmidt, R.E.; Garcia-Sastre, A. et al. IFN-stimulated gene 15 functions as a critical antiviral molecule against influenza, herpes, and Sindbis viruses. Proc. Natl. Acad. Sci. USA 104, 1371-1376.
84. Okumura, A.; Lu, G.; Pitha-Rowe, I.; Pitha, P.M. Innate antiviral response targets HIV-1 release by the induction of ubiquitin-like protein ISG15. Proc. Natl. Acad. Sci. USA 2006, 103, 1440-1445.
85. Okumura, A.; Pitha, P.M.; Harty, R.N. ISG15 inhibits Ebola VP40 VLP budding in an L-domain-dependent manner by blocking Nedd4 ligase activity. Proc. Natl. Acad. Sci. USA 105, 3974-3979.
86. Yuan, W.; Krug, R.M. Influenza B virus NS1 protein inhibits conjugation of the interferon (IFN)-induced ubiquitin-like ISG15 protein. EMBO J. 2001, 20, 362-371.
87. Tang, Y.; Zhong, G.; Zhu, L.; Liu, X.; Shan, Y.; Feng, H.; Bu, Z.; Chen, H.; Wang, C. Herc5 attenuates influenza A virus by catalyzing ISGylation of viral NS1 protein. J. Immunol. 2010, 184, 5777-5790.
88. Akutsu, M.; Ye, Y.; Virdee, S.; Chin, J.W.; Komander, D. Molecular basis for ubiquitin and ISG15 cross-reactivity in viral ovarian tumor domains. Proc. Natl. Acad. Sci. USA 2011, 108, 2228-2233.
89. Malakhova, O.A.; Yan, M.; Malakhov, M.P.; Yuan, Y.; Ritchie, K.J.; Kim, K.I.; Peterson, L.F.; Shuai, K.; Zhang, D.-E. Protein ISGylation modulates the JAK-STAT signaling pathway. Genes Dev. 2003, 17, 455-460.
90. Jeon, Y.J.; Choi, J.S.; Lee, J.Y.; Yu, K.R.; Kim, S.; Ka, S.H.; Oh, K.H.; Kim, K.I.; Zhang, D.-E.; Bang, O.S. et al. ISG15 modification of filamin B negatively regulates the type I interferon-induced JNK signalling pathway. EMBO Rep. 2009, 10, 374-380.
91. He, C.; Klionsky, D.J. Regulation mechanisms and signaling pathways of autophagy. Annu. Rev. Genet. 2009, 3, 67-93.
92. Hanada, T.; Ohsumi, Y. Structure-function relationship of Atg12, a ubiquitin-like modifier essential for autophagy. Autophagy 2005, 1, 110-118.
93. Ichimura, Y.; Kirisako, T.; Takao, T.; Satomi, Y.; Shimonishi, Y.; Ishihara, N.; Mizushima, N.; Tanida, I.; Kominami, E.; Ohsumi, M. et al. A ubiquitin-like system mediates protein lipidation. Nature 2000, 408, 488-492.
94. Kirisakoa, T.; Ichimura, Y.; Okadac, H.; Kabeyaa, Y.; Mizushimaa, N.; Yoshimoria, T.; Ohsumic, M.; Takaoe, T.; Nodaa, T.; Ohsumia, Y. The reversible modification regulates the membrane-binding state of APG8/AUT7 essential for autophagy and the cytoplasm to vacuole targeting pathway. J. Cell Biol. 2000, 151, 263-275.
95. Tanida, I.; Tanida-Miyake, E.; and, T.U. Kominami, E. The human homolog of saccharomyces cerevisiae APG7p is a protein-activating enzyme for multiple substrates including human APG12p, GATE-16, GABARAP, and MAP-LC3. J. Biol. Chem. 2001, 276, 1701-1706.
96. Shintani, T.; Mizushima, N.; Ogawa, Y.; Matsuura, A.; Noda, T.; Ohsum, Y. Apg10p, a novel protein-conjugating enzyme essential for autophagy in yeast. EMBO J. 1999, 18, 5234-5241.
97. Mizushima, N.; Noda, T.; Ohsumi, Y. Apg16p is required for the function of the Apg12p-Apg5p conjugate in the yeast autophagy pathway. EMBO J. 1999, 18, 3888-3896.
98. Radoshevich, L.; Murrow, L.; Chen, N.; Fernandez, E.; Roy, S.; Fung, C.; Debnath, J. ATG12 conjugation to ATG3 regulates mitochondrial homeostasis and cell death. Cell 2010, 142, 590-600.
99. Furukawa, K.; Mizushima, N.; Noda, T.; Ohsumi, Y. A protein conjugation system in yeast with homology to biosynthetic enzyme reaction of prokaryotes. J. Biol. Chem. 2000, 275, 7462-7465.
100. Singh, S.; Tonelli, M.; Tyler, R.C.; Bahrami, A.; Lee, M.S.; Markley, J.L. Three-dimensional structure of the AAH26994.1 protein from Mus musculus, a putative eukaryotic Urm1. Protein Sci. 2005, 14, 2095-2102.
101. Komatsu, M.; Chiba, T.; Tatsumi, K.; Iemura, S.; Tanida, I.; Okazaki, N.; Ueno, T.; Kominami, E.; Natsume, T.; Tanaka, K. A novel protein-conjugating system for Ufm1, a ubiquitin-fold modifier. EMBO J. 2004, 23, 1977-1986.
102. Tatsumi, K.; Sou, Y.-S.; Tada, N.; Nakamura, E.; Iemura, S.-I.; Natsume, T.; Kang, S.H.; Chung, C.H.; Kasahara, M.; Kominami, E. et al. A novel type of E3 ligase for the Ufm1 conjugation system. J. Biol. Chem. 2010, 285, 5417-5427.
103. Tatsumi, K.; Yamamoto-Mukai, H.; Shimizu, R.; Waguri, S.; Sou, Y.S.; Sakamoto, A.; Taya, C.; Shitara, H.; Hara, T.; Chung, C.H. et al. The Ufm1-activating enzyme Uba5 is indispensable for erythroid differentiation in mice. Nat. Commun. 2011, 2, 181.
104. Pugh, D.; Eiso, A.B.; Faro, A.; Lutya, P.; Hoffmann, E.; Rees, D.J. DWNN, a novel ubiquitin-like domain, implicates RBBP6 in mRNA processing and ubiquitin-like pathways. BMC Struct. Biol. 2006, 6, doi:10.1186/1472-6807-6-1.
105. Ntwasa, M. The retinoblastoma binding protein 6 is a potential target for therapeutic drugs. Biotechnol. Mol. Biol. Rev. 2008, 3, 24-31.
106. Li, L.; Deng, B.; Xing, G.; Teng, Y.; Tian, C.; Cheng, X.; Yin, X.; Yang, J.; Gao, X.; Zhu, Y., et al. PACT is a negative regulator of p53 and essential for cell growth and embryonic development. Proc. Natl. Acad. Sci. USA 2007, 104, 7951-7956.
107. Jones, S.N.; Roe, A.E.; Donehower, L.A.; Bradley, A. Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53. Nature 1995, 378, 206-208.
108. Shimizu, N.; Minoshima, S.; Asakawa, S. Cloning of Parkin gene and its function. No To Shinkei 51, 487-491.
109. Bronner, C.; Achour, M.; Arima, Y.; Chataigneau, T.; Saya, H.; Schini-Kerth, V.B. The UHRF family: Oncogenes that are drugable targets for cancer therapy in the near future? Pharmacol. Ther. 2007, 115, 419-434.
110. Masutani, C.; Sugasawa, K.; Yanagisawa, J.; Sonoyama, T.; Ui, M.; Enomoto, T.; Takio, K.; Tanaka, K.; van der Spek, P.J.; Bootsma, D. et al. Purification and cloning of a nucleotide excision repair complex involving the xeroderma pigmentosum group C protein and a human homologue of yeast RAD23. EMBO J. 1994, 13, 1831-1843.
111. Gamerdinger, M.; Hajieva, P.; Kaya, A.M.; Wolfrum, U.; Hartl, F.U.; Behl, C. Cloning and functional analysis of BAG-1: A novel Bcl-2-binding protein with anti-cell death activity. EMBO J. 2009, 28, 889-901.
112. Leznicki, P.; Clancy, A.; Schwappach, B.; High, S. Bat3 promotes the membrane integration of tail-anchored proteins. J. Cell Sci. 2010, 123, 2170-2178.
113. Sirkis, R.; Gerst, J.E.; Fass, D. Ddi1, a eukaryotic protein with the retroviral protease fold. J. Mol. Biol. 2006, 364, 376-387.
114. Hartmann, R.; Olsen, H.S.; Widder, S.; J0rgensen, R.; Justesen, J. p59OASL, a 2'-5' oligoadenylate synthetase like protein: A novel human gene related to the 2'-5' oligoadenylate synthetase family. Nucleic Acids Res. 1998, 26, 4121-4127.
115. Kokame, K.; Agarwala, K.L.; Kato, H.; Miyata, T. Herp, a new ubiquitin-like membrane protein induced by endoplasmic reticulum stress. J. Biol. Chem. 2000, 275, 32846-32853.
116. Ozaki, T.; Hishiki, T.; Toyama, Y.; Yuasa, S.; Nakagawara, A.; Sakiyama, S. Identification of a new cellular protein that can interact specifically with DAN. DNA Cell Biol. 1997, 16, 985-991.
117. Saia, X.; Kokame, K.; Shiraishia, H.; Kawamuraa, Y.; Miyata, T.; Yanagisawa, K.; Komano, H. The ubiquitin-like domain of herp is involved in Herp degradation, but not necessary for its enhancement of amyloid P-protein generation. FEBSLett. 2003, 553, 151-156.
118. Slodzinski, H.; Moran, L.B.; Michael, G.J.; Wang, B.; Novoselov, S.; Cheetham, M.E.; Pearce, R.K.; Graeber, M.B. Homocysteine-induced endoplasmic reticulum protein (Herp) is up-regulated in parkinsonian substantia nigra and present in the core of Lewy bodies. Clin. Neuropathol. 2009, 333-343.
119. Chan, S.L.; Fu, W.; Zhang, P.; Cheng, A.; Lee, J.; Kokame, K.; Mattson, M.P. Herp stabilizes neuronal Ca2+ homeostasis and mitochondrial function during endoplasmic reticulum stress. J. Biol. Chem. 2004, 279, 28733-28743.
120. Hori, O.; Ichinoda, F.; Yamaguchi, A.; Tamatani, T.; Taniguchi, M.; Koyama, Y.; Katayama, T.; Tohyama, M.; Stern, D.M.; Ozawa, K. et al. Role of Herp in the endoplasmic reticulum stress response. Genes Cells 2004, 9, 457-469.
121. Kitada, T.; Asakawa, S.; Minoshima, S.; Mizuno, Y.; Shimizu, N. Molecular cloning, gene expression, and identification of a splicing variant of the mouse parkin gene. Mamm. Genome 11, 417-421.
122. Kitada, T.; Asakawa, S.; Hattori, N.; Matsumine, H.; Yamamura, Y.; Minoshima, S.; Yokochi, M.; Mizuno, Y.; Shimizu, N. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 1998, 392, 605-608.
123. Shimura, H.; Hattori, N.; Kubo, S.-I.; Mizuno, Y.; Asakawa, S.; Minoshima, S.; Shimizu, N.; Iwai, K.; Chiba, T.; Tanaka, K. et al. Familial parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nat. Genet. 2000, 25, 302-305.
124. Cookson, M.R. Parkin's substrates and the pathways leading to neuronal damage. NeuroMol. Med. 2003, 3, 1-13.
125. Bae, Y.-J.; Kang, S.-J.; Park, K.S. Drosophila melanogaster Parkin ubiquitinates peanut and septin1 as an E3 ubiquitin-protein ligase. Insect Biochem. Mol. Biol. 2007, 37, 430-439.
126. Witte, M.M.; Scott, R.E. The proliferation potential protein-related (P2P-R) gene with domains encoding heterogeneous nuclear ribonucleoprotein association and Rb1 binding shows repressed expression during terminal differentiation. Proc. Natl. Acad. Sci. USA 1997, 94, 1212-1217.
127. Simons, A.; Melamed-Bessudo, C.; Wolkowicz, R.; Sperling, J.; Sperling, R.; Eisenbach, L.; Rotter, V. PACT: Cloning and characterization of a cellular p53 binding protein that interacts with Rb. Oncogene 1997, 14, 145-155.
128. Scott, R.E.; Giannakouros, T.; Gao, S.; Peidis, P. Functional potential of P2P-R: A role in the cell cycle and cell differentiation related to its interactions with proteins that bind to matrix associated regions of DNA? J. Cell Biochem. 2003, 90, 6-12.
129. Conklina, D.; Holdermana, S.; Whitmoreb, T.E.; Maurerb, M.; Feldhaus, A.L. Molecular cloning, chromosome mapping and characterization of UBQLN3 a testis-specific gene that contains an ubiquitin-like domain. Gene 2000, 249, 91-98.
130. Ko, H.S.; Uehara, T.; Nomura, Y. Role of ubiquilin associated with protein-disulfide isomerase in the endoplasmic reticulum in stress-induced apoptotic cell death. J. Biol. Chem. 2002, 277, 35386-35392.
131. Hoeller, D.; Hecker, C.-M.; Dikic, I. Ubiquitin and ubiquitin-like proteins in cancer pathogenesis. Nat Rev Cancer 2006, 6, 776-788.
132. Liu, M.; Hummer, T.; Li, X.; Hassel, B.A. Camptothecin induces the ubiquitin-like protein, ISG15, and enhances ISG15 conjugation in response to interferon. J. Interferon Cytokine Res. 2004, 24, 647-654.
133. Ohwada, S.; Kobayashi, I.; Maemura, M.; Satoh, Y.; Ogawa, T.; Iino, Y.; Morishita, Y. Interferon potentiates antiproliferative activity of CPT-11 against human colon cancer xenografts. Cancer Lett. 1996, 110, 149-154.
134. Yang, Y.; Kitagaki, J.; Wang, H.; Hou, D.-X.; Perantoni, A.O. Targeting the ubiquitin-proteasome system for cancer therapy. Cancer Sci. 2009, 100, 24-28.
135. Richardson, P.G.; Barlogie, B.; Berenson, J.; Singhal, S.; Jagannath, S.; Irwin, D.; Rajkumar, S.V.; Srkalovic, G.; Alsina, M.; Alexanian, R. et al. A Phase 2 study of Bortezomib in relapsed, refractory myeloma. N. Engl. J. Med. 2003, 348, 2609-2617.
136. Jagannath, S.; Barlogie, B.; Berenson, J.; Siegel, D.; Irwin, D.; Richardson, P.G.; Niesvizky, R.; Alexanian, R.; Limentani, S.A.; Alsina, M. et al. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br. J. Haematol. 2004, 127, 165-172.
137. Orlowski, R.Z.; Nagler, A.; Sonneveld, P.; Blade, J.; Hajek, R.; Spencer, A.; San Miguel, J.; Robak, T.; Dmoszynska, A.; Horvath, N. et al. Randomized Phase III study of Pegylated liposomal Doxorubicin plus Bortezomib compared with Bortezomib alone in relapsed or refractory multiple myeloma: Combination therapy improves time to progression. J. Clin. Oncol. 25, 3892-3901.
138. National Cancer Institute. Fda approval for Bortezomib. Available online: http://www.cancer.gov/cancertopics/druginfo/fda-bortezomib (accessed on 1 June 2012).
139. Kane, R.C.; Bross, P.F.; Farrell, A.T.; Pazdur, R. Velcade®: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy. Oncologist 2003, 8, 508-513.
140. Sun, Y. Targeting E3 ubiquitin ligases for cancer therapy. Cancer Biol. Ther. 2003, 2, 623-629.
141. Saha, M.N.; Jiang, H.; Jayakar, J.; Reece, D.; Branch, D.R.; Chang, H. MDM2 antagonist nutlin plus proteasome inhibitor velcade combination displays a synergistic anti-myeloma activity. Cancer Biol. Ther. 2010, 9, 936-944.
142. Bettermann, K.; Benesch, M.; Weis, S.; Haybaeck, J. SUMOylation in carcinogenesis. Cancer Lett. 2012, 316, 113-125.
143. Mo, Y.-Y.; Moschos, S.J. Targeting Ubc9 for cancer therapy. Expert Opin. Ther. Tar 2005, 9, 1203-1216.
144. Weisshaar, S.R.; Keusekotten, K.; Krause, A.; Horst, C.; Springer, H.M.; Gottsche, K.; Dohmen, R.J.; Praefcke, G.J.K. Arsenic trioxide stimulates SUMO-2/3 modification leading to RNF4-dependent proteolytic targeting of PML. FEBSLett. 2008, 582, 3174-3178.
145. Miller, W.H.; Schipper, H.M.; Lee, J.S.; Singer, J.; Waxman, S. Mechanisms of action of arsenic trioxide. Cancer Res. 2002, 62, 3893-3903.
146. Hoeller, D.; Dikic, I. Targeting the ubiquitin system in cancer therapy. Nature 2009, 458, 438-444.
147. Soucy, T.A.; Smith, P.G.; Milhollen, M.A.; Berger, A.J.; Gavin, J.M.; Adhikari, S.; Brownell, J.E.; Burke, K.E.; Cardin, D.P.; Critchley, S. et al. An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer. Nature 2009, 458, 732-736.
148. Cohen, P.; Tcherpakov, M. Will the ubiquitin system furnish as many drug targets as protein kinases? Cell 2010, 143, 686-693.
149. Colland, F.; Formstecher, E.; Jacq, X.; Reverdy, C.; Planquette, C.; Conrath, S.; Trouplin, V.; Bianchi, J.; Aushev, V.N.; Camonis, J. et al. Small-molecule inhibitor of USP7/HAUSP ubiquitin protease stabilizes and activates p53 in cells. Mol. Cancer Ther. 2009, 8, 2286-2295.